Expanding Oncology Portfolio
Celltrion Receives FDA Approval for Phase 3 Clinical Trial of Keytruda Biosimilar in the U.S.
Celltrion announced on the 12th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 Investigational New Drug (IND) application for 'CT-P51', a biosimilar to…